On November 4, 2021 Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported that two abstracts related to the Company’s selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA (Press release, Vincerx Pharma, NOV 4, 2021, View Source [SID1234594364]). The following abstracts were published today and are now available on the ASH (Free ASH Whitepaper) website at www.hematology.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
VIP152, a selective CDK9 inhibitor, induces complete regression of high-grade B-cell lymphoma (HGBL) models and depletion of short-lived oncogenic driver transcripts, MYC and MCL1, with a once weekly schedule. (Abstract #1192)
Session Name: Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
Date: Saturday, December 11, 2021
Time: Poster viewing 9:00am-7:30pm; presenters available 5:30-7:30pm ET
Location: Hall B5
VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia (Abstract #270)
Session Name: Chemical Biology and Experimental Therapeutics
Date: Saturday, December 11, 2021
Time: Oral Presentation at 3:15 ET
Location: Georgia World Congress Center, C108-C109